Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech vs. Shorts -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (14)	7/26/1999 12:32:00 PM
From: Vector1	Read Replies (4) \| Respond to of 427

Rick, Prudential/Vector analyst Johm Sonnier did not help us today. He put a hold on GLIA stock based on the risk of decellerating Adcon sales and price runup. What run up? I do not know this guy but the analysis is less than impressive. ------------- (snip)We are encouraged by the progress of the therapeutic division, which we do not believe has received adequate attention. This year, Gliatech should see an active news calendar, with the completion of two pivotal trials for additional ADCON products and Japanese approval of ADCON-L. However, as the stock has appreciated over 50% in the past 12 months, and as we believe the momentum of ADCON-L sales could see some slow down, we believe the shares are fairly valued at current levels. We expect fully taxed earnings in 1999, 2000, and 2001 of $0.14, $0.48, and $0.61, respectively.(snip) V1